Table 1.
Baseline clinico-pathological characteristics of breast cancer patients.
| Characteristics | N | % |
|---|---|---|
| Median age, years (range) | 52.0 (24-82) | |
| Age, years | ||
| <50 | 67 | 42.9 |
| ≥50 | 89 | 57.1 |
| Menstrual status | ||
| Pre/peri-menopausal | 72 | 46.2 |
| Post-menopausal | 84 | 53.8 |
| Neoadjuvant treatment | ||
| Yes | 30 | 19.2 |
| No | 126 | 80.8 |
| Breast surgery | ||
| Mastectomy | 114 | 73.1 |
| BCS | 42 | 26.9 |
| Axillary surgery | ||
| None | 6 | 3.8 |
| SLNB | 45 | 28.8 |
| ALND | 105 | 67.3 |
| Histological type | ||
| IDC | 127 | 81.4 |
| Non-IDC | 29 | 18.6 |
| Histological grade | ||
| I-II | 72 | 46.2 |
| III | 77 | 49.4 |
| NA | 7 | 4.5 |
| pT | ||
| is | 20 | 12.8 |
| 1-2 | 126 | 80.8 |
| 3-4 | 10 | 6.4 |
| pN | ||
| 0, x* | 81 | 51.9 |
| 1-3 | 75 | 48.1 |
| ER status | ||
| Positive | 94 | 60.3 |
| Negative | 62 | 39.7 |
| PR status | ||
| Positive | 58 | 37.2 |
| Negative | 98 | 62.8 |
| HER2 status | ||
| Positive | 42 | 26.9 |
| Negative | 98 | 62.8 |
| Uncertain** | 16 | 10.3 |
| Ki67 status | ||
| <14% | 50 | 32.1 |
| ≥14% | 106 | 67.9 |
| DFI | ||
| <2 years | 59 | 37.8 |
| ≥2 years | 97 | 62.2 |
| Recurrent Site | ||
| LRR | 70 | 44.9 |
| Viscera | 52 | 33.3 |
| Bone or soft tissue | 34 | 21.8 |
*pN was not available in 6 patients who did not have axillary surgery.
**16 patients were defined as HER2 2+ in IHC test but did not undergo FISH testing.
BCS, breast-conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; IDC, invasive ductal carcinoma; NA, not available; pT, pathological tumor size stage; pN, pathological lymph node stage; is, in situs; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; DFI, disease free interval; LRR, loco-regional recurrence.